Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00571116 · ClinicalTrials.gov registry record · Phase 1
Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy
A Phase 1 study, sponsored by University of California, Irvine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00571116 is a Phase 1 study that was terminated before completion, run by University of California, Irvine. The registered enrollment target is 9 participants.
The verdict
NCT00571116, a Phase 1 study, was terminated before completion, sponsored by University of California, Irvine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of arsenic trioxide when given together with disulfiram in treating patients with metastatic and progressive melanoma. Drugs used in chemotherapy, such as disulfiram and arsenic trioxide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
Interventions
- DRUG Disulfiram
- DRUG Arsenic trioxide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2006-09 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00571116
The ClinicalTrials.gov registry entry for NCT00571116 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Disulfiram is the first listed.
NCT00571116 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00571116 about?
NCT00571116 is a clinical study titled "Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy". This phase I trial is studying the side effects and best dose of arsenic trioxide when given together with disulfiram in treating patients with metastatic and progressive melanoma. Drugs used in chemotherapy, such as disulfiram and arsenic trioxide, work in different ways to stop the growth of tumor...
What is the current status of trial NCT00571116?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2006-09. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00571116?
The interventions under investigation include: Disulfiram (DRUG), Arsenic trioxide (DRUG).
Who is sponsoring clinical trial NCT00571116?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.